• Who We Are
    • About Us
    • Leadership
    • Member Partners
    • International Advisory Board
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • About the Issue
    • FAQs
    • Naming
    • Substitution Policy
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • European Union
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos

Safe Biologics

  • Safe Biologics

  • Who We Are
    • About Us
    • Leadership
    • Member Partners
    • International Advisory Board
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • About the Issue
    • FAQs
    • Naming
    • Substitution Policy
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • European Union
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos
worldflags

Whitepapers

A Critical Review of Substitution Policies for Biosimilars in Canada (GaBI Journal, 2021)

US Biosimilar Market on Pace with Europe (GaBI Journal, 2020)

European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution  (GaBI Journal, 2020)

Policy recommendations for a sustainable biosimilars market: lessons from Europe (GaBI Journal, 2020)

Medicines regulation in the MENA Region and the importance of the World Health Organization’s INN proposal of Biological Qualifier (GaBI Journal, 2018)

A survey of Australian prescribers’ views on the naming and substitution of biologicals (GaBI Journal, 2017)

Naming and labelling of biologicals – a survey of US physicians’ perspectives (GaBI Journal, 2017)

Clear naming, traceability of biological medicines will protect patients (GaBI Journal, 2017)

Naming and labelling of biologicals – the perspective of hospital and retail pharmacists (GaBI Journal, 2015)

Prescribing practices for biosimilars: questionnaire survey findings from physicians in Argentina, Brazil, Colombia and Mexico (GaBI Journal, 2015)

Biosimilars naming, label transparency and authority of choice – survey findings among European physicians (GaBI Journal, 2014)

The future of biological therapy: a pathway forward for biosimilars (GaBI Journal, 2013)

‘It’s all about the name: what is the imperative of adopting unique names for biologic and biosimilar therapeutics?’ (Food and Drug Law Institute, 2012)

 

Latest News

ASBM’s Feldman and Reilly Present at Treatment Choice Summit

On January 31st, ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR and Executive Director Michael Reilly participated in the 2023 Treatment Choice Summit, held in Washington, DC. Dr. Feldman moderated the first panel discussion, Patient and Provider Perspectives on the Impact of Treatment Choice. The purpose of the discussion was to identify barriers to treatment choice and […]

Read More

Ontario Announces Forced-Substitution Policy

In December, the Ontario government announced that it would follow other Canadian provinces including British Columbia, Alberta, Quebec and require mandatory switching to biosimilars.  a mandatory switching in 2020, but implementation was delayed due to the COVID-19 pandemic. A nine-month transition period will begin March 31st. From the government’s announcement: Ontarians receiving coverage under the ODB […]

Read More

ASBM Members: Get Free Access to ASBM/OSU Biosimilars Course

The Ohio State College of Pharmacy has provided ASBM with access codes for our Members who wish to view the first four modules of the ASBM/OSU College of Pharmacy Biosimilars Course at no charge: Biosimilars Module 1: Introduction to Biologics and Biosimilars  (Prof. Philip Schneider, MS FASHP FFIP) Biosimilars Module 2: Substitution and Interchangeability (Prof. Philip Schneider, MS FASHP […]

Read More

logo logo logo
logo

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups — from patients to physicians, medical innovators, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Contact Us

Who we are
  • About Us
  • Leadership
  • Member Partners
  • International Advisory Board
News
  • Latest News
  • Letters
  • Newsletter
  • Press Releases
  • Recent Events
The Issue
  • About the Issue
  • FAQs
  • Naming
  • Substitution Policy
  • Biologic Safety
  • BIO Principles
Policy
  • Australia
  • Canada
  • European Union
  • FDA
  • FDA Guidance
  • In the States
Resources
  • Surveys
  • Courses
  • Webinars